Healthcare Services

One of the Major Drivers of the Leukocyte Adhesion Deficiency Management Market Is the Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency.

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Leukocyte Adhesion Deficiency Management Market Projected To Become By 2030 Based On Its 2026 Valuation?

The size of the leukocyte adhesion deficiency management market has experienced significant growth in recent years. This market is projected to expand from $8.59 billion in 2025 to $9.16 billion in 2026, registering a compound annual growth rate (CAGR) of 6.6%. The historical growth can be attributed to factors such as limited treatment options for rare immunodeficiency disorders, high infection-related mortality rates, reliance on antimicrobial therapy, low awareness of leukocyte adhesion deficiency, and restricted access to advanced transplantation facilities.

The leukocyte adhesion deficiency management market is anticipated to experience robust expansion in the coming years. It is projected to reach $12.2 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.4%. This projected growth can be attributed to enhancements in stem cell transplantation techniques, the increasing accessibility of genetic testing, escalating investments in rare disease research, the rising embrace of personalized immunotherapy, and the establishment of more specialized immunology care centers. Significant trends expected during the forecast period involve the wider implementation of hematopoietic stem cell transplantation, the growing acceptance of gene-based diagnostic testing, increased application of prophylactic immunoglobulin therapy, a sharpened focus on early infection prevention, and ongoing advancements in targeted immunomodulatory treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13172&type=smp

Which Market Drivers Are Supporting The Expansion Of The Leukocyte Adhesion Deficiency Management Market?

The leukocyte adhesion deficiency management market is anticipated to experience growth driven by the increasing prevalence of primary immunodeficiency. Primary immunodeficiency (PID) encompasses a group of inherited disorders that compromise the body’s immune system, leaving individuals more vulnerable to infections and illnesses due to deficiencies in their immune responses. Managing leukocyte adhesion deficiency offers benefits to primary immunodeficiency by advancing insights into immune system disorders and potentially fostering improved diagnostic tools and therapies relevant to both conditions. For instance, in April 2023, data gathered from World Primary Immunodeficiency (WPI) Awareness Week 2023, as reported by the India-based multi-specialty Peace Hospital, indicated that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, with 70% to 90% of these individuals having undiagnosed primary immunodeficiency. Consequently, the rising occurrence of primary immunodeficiency is poised to fuel the expansion of the leukocyte adhesion deficiency management market.

What Segment Groups Are Identified Within The Leukocyte Adhesion Deficiency Management Market?

The leukocyte adhesion deficiency management market covered in this report is segmented –

1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation

2) By Diagnosis: Blood Test, Genetic Testing

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Hematopoietic Stem Cell Transplantation: Related Donor Transplant, Unrelated Donor Transplant

2) By Recombinant Human Interferon-Gamma Treatment: Standard Dosing, Customized Dosing

3) By Prophylactic Immunoglobulin Therapy: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)

4) By Antimicrobial Therapy: Antibiotics, Antifungal Treatments

5) By Prophylactic Therapy: Vaccination Strategies, Infection Prevention Protocols

6) By Fucose Supplementation: Oral Supplements, Intravenous Supplements

How Are Trends Shaping The Direction Of The Leukocyte Adhesion Deficiency Management Market?

Leading companies in the leukocyte adhesion deficiency management market are advancing lentiviral vector-based gene therapy technology to refine targeted therapies and improve patient results. This gene therapy provides a precise method in leukocyte adhesion deficiency management by delivering corrective genes directly into cells, potentially restoring immune system function. For example, in February 2024, Rocket Pharmaceuticals, a US-based biotechnology company, introduced kresladi (marnetegragene autotemcel) for the treatment of severe leukocyte adhesion deficiency-I (LAD-I). A Phase 1/2 study revealed it achieved 100% survival at 12 months, substantially decreasing infections and alleviating symptoms. Kresladi presents a pioneering choice in the LAD management market, addressing crucial unfulfilled needs.

Which Companies Hold Significant Positions In The Leukocyte Adhesion Deficiency Management Market?

Major companies operating in the leukocyte adhesion deficiency management market are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

Read the full leukocyte adhesion deficiency management market report here:

https://www.thebusinessresearchcompany.com/report/leukocyte-adhesion-deficiency-management-global-market-report

How Is The Leukocyte Adhesion Deficiency Management Market Distributed Across Key Geographic Regions?

North America was the largest region in the leukocyte adhesion deficiency management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leukocyte Adhesion Deficiency Management Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13172&type=smp

Browse Through More Reports Similar to the Global Leukocyte Adhesion Deficiency Management Market 2026, By The Business Research Company

Acquired Hemophilia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Hepatitis Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Hyperhidrosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/hyperhidrosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795